Impact of pre-chemotherapy locomotive syndrome status on short-term adverse outcome events in elderly lung cancer patients: A longitudinal study

Table 1 Comparison of general information between the locomotive syndrome group and the non-locomotive syndrome group, n (%)

Item	LS group (n = 161)	Non-LS group (n = 225)	χ2/t/Z	P value
Gender (M/F)	57/104	110/115	4.783	0.058
Age (mean ± SD), years	69.2 ± 7.2	70.1 ± 6.9	-0.894	0.423
Educational level			1.982	0.221
Junior high school and below	79 (48.9)	89 (39.6)
High school and above	82 (51.1)	136 (60.4)
Living status			4.894	0.094
With cohabitants	98 (60.9)	157 (69.8)
Live alone	63 (39.1)	68 (30.2)
Residency			2.567	0.223
Rural	53 (32.9)	92 (40.9)
Towns	108 (67.1)	133 (59.1)
Pathological type			1.434	0.323
Adenocarcinoma	122 (75.8)	152 (67.6)
Squamous carcinoma	39 (24.2)	73 (32.4)
Staging of the tumor			0.468	0.398
Stage II	73 (45.3)	111 (49.3)
Stage III	88 (54.7)	114 (50.7)
LS after chemotherapy			78.066	< 0.001
Yes	161 (100)	87 (38.7)
No	0 (0)	138 (61.3)

M: Male; F: Female; LS: Locomotive syndrome.

Table 2 Comparison of the number and grading of toxic side effects during chemotherapy between the locomotive syndrome group and the non-locomotive syndrome group, n (%)

Group	n	Toxic side effects (mean ± SD)	Grading of toxic side effects
			Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
LS group	161	16.1 ± 3.8	27 (16.7)	36 (22.4)	38 (23.6)	36 (22.4)	24 (14.9)
Non-LS group	225	11.3 ± 4.1	52 (23.1)	68 (30.3)	75 (33.3)	20 (8.9)	10 (4.4)
t/Z		14.127	3.234
P value		< 0.001	0.006

LS: Locomotive syndrome.

Table 3 Comparison of incapacitation during the follow-up period between the locomotive syndrome group and the non-locomotive syndrome group, n (%)

Group	n	Incapacitation			Unplanned hospitalization rate
		Complete incapacitation	Moderate incapacitation	Non-incapacitation
LS group	144	22 (15.3)	39 (26.8)	83 (57.9)	54 (37.2)
Non-LS group	218	7 (3.4)	24 (10.8)	187 (85.8)	22 (10.1)
Z/χ2		-5.454			20.113
P value		< 0.001			< 0.001

LS: Locomotive syndrome.